- Home
- GYRO vs IBIO Comparison
GYRO vs IBIO Comparison
Compare GYRO & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRO
- IBIO
- Stock Information
- Founded
- GYRO 1946
- IBIO 2008
- Country
- GYRO United States
- IBIO United States
- Employees
- GYRO N/A
- IBIO N/A
- Industry
- GYRO Building operators
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GYRO Real Estate
- IBIO Health Care
- Exchange
- GYRO Nasdaq
- IBIO Nasdaq
- Market Cap
- GYRO 23.1M
- IBIO 23.4M
- IPO Year
- GYRO N/A
- IBIO N/A
- Fundamental
- Price
- GYRO $10.39
- IBIO $2.18
- Analyst Decision
- GYRO
- IBIO Strong Buy
- Analyst Count
- GYRO 0
- IBIO 2
- Target Price
- GYRO N/A
- IBIO $4.30
- AVG Volume (30 Days)
- GYRO 2.3K
- IBIO 97.7K
- Earning Date
- GYRO 01-01-0001
- IBIO 11-12-2024
- Dividend Yield
- GYRO N/A
- IBIO N/A
- EPS Growth
- GYRO N/A
- IBIO N/A
- EPS
- GYRO N/A
- IBIO N/A
- Revenue
- GYRO $2,738,019.00
- IBIO $175,000.00
- Revenue This Year
- GYRO N/A
- IBIO N/A
- Revenue Next Year
- GYRO N/A
- IBIO N/A
- P/E Ratio
- GYRO N/A
- IBIO N/A
- Revenue Growth
- GYRO N/A
- IBIO 250.00
- 52 Week Low
- GYRO $7.65
- IBIO $1.02
- 52 Week High
- GYRO $11.96
- IBIO $6.20
- Technical
- Relative Strength Index (RSI)
- GYRO 62.21
- IBIO 42.02
- Support Level
- GYRO $10.30
- IBIO $2.32
- Resistance Level
- GYRO $10.69
- IBIO $2.65
- Average True Range (ATR)
- GYRO 0.04
- IBIO 0.19
- MACD
- GYRO -0.09
- IBIO -0.06
- Stochastic Oscillator
- GYRO 22.50
- IBIO 13.54
About GYRO Gyrodyne LLC
Gyrodyne LLC is a United States-based limited liability company. It operates in the ownership and management of industrial and medical office buildings segment. The company leases and manages various commercial properties such as medical offices and industrial properties. The properties owned by the company include Cortlandt Manor and Flowerfield.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.